This Product Review discusses the use of nivolumab plus ipilimumab for the first-line treatment of intermediate- or poor-risk, advanced renal cell carcinoma.
This review discusses the evidence in support of the use of this approach, currently available treatments, the drugs’ pharmacology including mechanism of action, and efficacy and tolerability as demonstrated in pivotal clinical trials. It also provides commentary and recommendations from Dr. Laurence Krieger, lead clinician and Principal Investigator for numerous clinical trials in urogenital malignancies at the Northern Cancer Institute, Sydney and Consultant General Physician and tutor for the University of Sydney.
Please login below to download this issue (PDF)